中子捕获疗法的副作用
1Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Journal of cancer research and therapeutics
|September 4, 2025
概括
中子捕获疗法 (BNCT) 对于癌症治疗具有前景,但可能引起副作用. 了解这些不良事件是提高BNCT对患者的安全性和有效性的关键.
科学领域:
- 癌症学
- 辐射瘤学
- 医学物理
背景情况:
- 中子捕获疗法 (BNCT) 是一种针对瘤细胞的二元癌症治疗方法.
- 临床应用包括各种癌症,如质瘤,头癌和黑色素瘤.
- BNCT的不良影响对其广泛的临床采用构成挑战.
研究的目的:
- 从临床研究中系统地审查BNCT的不良影响.
- 分析BNCT副作用的机制,促成因素和瘤特异性变异.
- 突出管理策略,并确定未来的BNCT安全研究需求.
主要方法:
- 对BNCT不良影响的临床研究的系统审查.
- 根据瘤类型,中子源和传递剂报告的副作用分析.
- 检查治疗方案及其对BNCT相关毒性的影响.
主要成果:
- 与BNCT相关的不良反应因瘤类型,中子源,递送剂和治疗方案而异.
- 在不同恶性瘤中确定了这些副作用的机制和促成因素.
- 观察到瘤特异性的不良反应,影响治疗结果.
结论:
- 了解BNCT的副作用对于优化治疗方案至关重要.
- 讨论目前的管理和预防策略,以及需要进一步研究的领域.
- 这一审查支持开发更安全的BNCT准确瘤学方法.
相关概念视频
Biological Effects of Radiation
15.9K
All radioactive nuclides emit high-energy particles or electromagnetic waves. When this radiation encounters living cells, it can cause heating, break chemical bonds, or ionize molecules. The most serious biological damage results when these radioactive emissions fragment or ionize molecules. For example, α and β particles emitted from nuclear decay reactions possess much higher energies than ordinary chemical bond energies. When these particles strike and penetrate matter, they...
15.9K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321
Skeletal Muscle Relaxants: Adverse Effects
467
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
467
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259


